Via immunohistochemistry and RNA sequencing methods, prominent reduction of matrix constituents including DCN has been detected in the microenvironment of many solid malignancy tissues [61], including breast cancers [59], prostate cancers [62], haemangiomas [63], hepatocellular carcinomas [64], low-high grade urothelial tumours [65], oesophageal squamous cell carcinomas [66], colon cancers [67] and multiple myeloma [68]. This evidence concerns the gene DCN and breast carcinoma.